|Bid||164.30 x 1400|
|Ask||172.00 x 800|
|Day's Range||164.33 - 165.44|
|52 Week Range||123.73 - 177.51|
|PE Ratio (TTM)||11.77|
|Forward Dividend & Yield||1.05 (0.62%)|
|1y Target Est||N/A|
The $62 billion Shire takeover, which Takeda expects to close in the first half of 2019, will create the the largest life sciences employer in Massachusetts.
Roche jumped early Monday on unsurprisingly strong data for its hemophilia treatment, Hemlibra — prodding shares of Shire to slip.
will strengthen the Japanese group’s focus on innovative medicines and make it more “resilient” to pricing pressures in the US, its chief executive has said. , Mr Weber said, had been designed “in a way” that meant the combined company “would be very resilient and prepared for an environment which will become tougher”. In 2017, the US accounted for 66 per cent of Shire’s $15bn sales.
The biotech analysts at Cantor Fitzgerald have a packed calendar: here are some of the dates they’re tracking and why they’re important. Mallinckrodt PLC (NYSE: MNK ) is expected to release Phase 4 interim ...
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical , securing a $62 billion (46 billion pound) deal last week to buy drugmaker Shire (SHP.L) at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor.
The FDA’s decision to publish a list of companies accused of blocking access to their product samples is part of a broader effort by the Trump administration to address high drug costs.
For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit. At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more long-term, large strategic investor. When you combine two pipelines you can be more stringent," he said in London, where he is meeting investors and analysts.
I am going to run you through how I calculated the intrinsic value of Shire plc (LSE:SHP) using the discounted cash flow (DCF) method. If you want to learn moreRead More...
Companies, such as Trading Emissions, trading at a market price below their true values are considered to be undervalued. There’s a few ways you can determine how much a companyRead More...
Shire had been planning to move into the building early next year. Takeda's $62 billion buyout this week could throw a wrench in the works.
In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application (or sNDA) to the FDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric patients with narcolepsy. In April, Jazz Pharmaceuticals entered into an agreement with Spark Therapeutics (ONCE) whereby Jazz would purchase a rare pediatric disease priority review voucher for $110 million that would allow it to accelerate the FDA review process for one of its future regulatory submissions. Of the 23 analysts tracking Jazz Pharmaceuticals in May, six have recommended “strong buys” on the stock, while 13 have recommended “buys.” Four analysts have recommended “holds” on Jazz Pharmaceuticals in May.
In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.
Takeda Pharmaceutical Co.’s ambitions for expansion in the lucrative U.S. health-care market led the Japanese drugmaker to begin a painstaking examination of Shire Plc’s assets more than two years prior to striking a $62 billion deal. In particular, Shire’s neuroscience unit and its gastrointestinal products sparked Takeda’s interest. Shire’s struggling stock performance after its failed sale to AbbVie Inc. and the acquisition spree that followed, culminating with the $32 billion takeover of Baxalta Inc., frustrated investors and prompted concerns about its strategy.
Takeda Pharmaceutical Co. investors may belatedly be coming around to the view that the $62 billion purchase of Shire Plc is the best thing that could have happened to the Japanese drugmaker. To get the same U.S. exposure, and generate cost savings, Takeda might have looked to Celgene Corp. or Biogen Inc., according to Datamonitor Healthcare analyst Edward Thomason. Tack on the 65 percent premium Takeda offered Shire shareholders and you’re talking an awful lot of money.
Moody's Investors Service ("Moody's") placed the ratings of Shire plc ("Shire") and subsidiaries under review for upgrade. This rating action follows the announcement that Shire's board recommends that shareholders vote in favor of Takeda Pharmaceutical Company Limited's offer to acquire Shire for approximately JPY6.7 trillion (USD62 billion). Takeda's rating is A2 under review for possible downgrade, and the rating review of Shire will be tied to the ongoing rating review of Takeda.
Takeda Pharmaceutical Co.’s credit rating was downgraded by Moody’s Investors Service one day after the Japanese drugmaker said it had reached a deal to buy larger rival Shire Plc for about $62 billion. Takeda’s debt rating was cut to A2 from A1 on Wednesday, bringing it down one notch to the sixth-highest investment-grade level. Chief Executive Officer Christophe Weber capped a drawn-out pursuit of the U.K.-listed company on Tuesday, announcing an acquisition that will give Takeda wider reach into the U.S., the world’s biggest drug market, and strengthen its global pipeline.
Moody's Japan K.K. has downgraded to A2 from A1 the issuer and senior unsecured ratings of Takeda Pharmaceutical Company Limited. Moody's has also placed Takeda's A2 issuer and senior unsecured ratings under review for further downgrade following Takeda's announcement on 8 May 2018 that it will acquire all of the outstanding shares in Shire plc (Baa3 positive) for approximately JPY7 trillion (USD64 billion). Prior to the Shire announcement, Takeda's rating outlook had been negative due to elevated leverage after a previous major acquisition last year.
Takeda Pharmaceutical Co.’s Chief Executive Officer Christophe Weber navigated rebuffs, critics and a plunging stock price to win a $62 billion deal to acquire larger rival Shire Plc. Integrating the Japanese drugmaker -- which began by selling herbal therapies 237 years ago -- with the sprawling American company will be even more complicated. As the Osaka-based company’s first foreign head, Weber is overseeing a dramatic makeover that will reshape Takeda into a global powerhouse with a plum suite of drugs for rare diseases.
Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC, capping a monthslong battle for control of the European drugmaker and marking the biggest-ever overseas acquisition by a Japanese company. Shire’s board agreed Takeda could buy it at £49.01 or $66.21 a share—$30.33 in cash and 0.839 of a Takeda share for each Shire share—in a deal that valued the target at $62 billion. The acquisition would create the world’s eighth-largest drugmaker with combined sales worth $30 billion, and bolsters Takeda Chief Executive Christophe Weber’s mission to gain a greater foothold in more lucrative markets such as the U.S. and Europe.
Andy Plump, Takeda’s chief medical and scientific officer based in Cambridge, said the deal was partly driven by the company’s desire to expand further into the lucrative market for orphan drugs.
U.K. stocks booked a tiny loss Tuesday, as oil-and-gas shares fell along with oil futures ahead of a closely watched decision on a resumption of Iranian sanctions by the U.S. However, the day’s loss was limited by optimism over a $62 billion takeover offer for Shire.